Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Harold L. Moses

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0116-0140; OpenAlex author ID A5045030798. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 8

  1. Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/s41591-023-02694-w↗
  2. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Co-author DOI 10.1038/s41598-020-78320-3↗
  3. Blocking CXCLs-CXCR2 axis in tumor-stromal interactions contributes to survival in a mouse model of pancreatic ductal adenocarcinoma through reduced cell invas… Co-author DOI 10.1038/s41389-018-0117-8↗
  4. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/nm.4082↗
  5. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model … Co-author DOI 10.1053/j.gastro.2015.07.058↗
  6. Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. Co-author DOI 10.1111/cas.12080↗
  7. Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Co-author DOI 10.1158/0008-5472.can-12-1453↗
  8. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. Last author DOI 10.1172/jci42754↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuhiko Koike · 5 shared papers, 2011–2020 · strength 0.25
  2. Hideaki Ijichi · 5 shared papers, 2011–2020 · strength 0.25
  3. Koji Miyabayashi · 4 shared papers, 2011–2020 · strength 0.22
  4. Alex Barrett · 2 shared papers, 2016–2024 · strength 0.20
  5. Grace Kim · 2 shared papers, 2016–2024 · strength 0.20
  6. Hanane Laklai · 2 shared papers, 2016–2024 · strength 0.20
  7. Nilotpal Roy · 2 shared papers, 2016–2024 · strength 0.20
  8. Matthias Hebrok · 2 shared papers, 2016–2024 · strength 0.20
  9. Laura DeLong Wood · 2 shared papers, 2016–2024 · strength 0.20
  10. Eric Andrew Collisson · 2 shared papers, 2016–2024 · strength 0.20
  11. Raghu Kalluri · 2 shared papers, 2016–2024 · strength 0.20
  12. Valerie Marie Weaver · 2 shared papers, 2016–2024 · strength 0.20
  13. Julia Sidenius Johansen · 2 shared papers, 2016–2024 · strength 0.20
  14. Christine A. Iacobuzio–Donahue · 2 shared papers, 2016–2024 · strength 0.20
  15. Kirk Charles Hansen · 2 shared papers, 2016–2024 · strength 0.20
  16. Ryota Takahashi · 3 shared papers, 2013–2020 · strength 0.20
  17. Hiroyuki Isayama · 3 shared papers, 2013–2020 · strength 0.20
  18. Makoto Sano · 2 shared papers, 2019–2020 · strength 0.17
  19. Dai Mohri · 3 shared papers, 2011–2020 · strength 0.14
  20. Keisuke Yamamoto · 2 shared papers, 2013–2020 · strength 0.12
  21. Yousuke Nakai · 2 shared papers, 2013–2020 · strength 0.12
  22. Gen Kimura · 1 shared paper, 2020 · strength 0.09
  23. Tomoharu Yamada · 1 shared paper, 2019 · strength 0.08
  24. Hiroyuki Kato · 1 shared paper, 2019 · strength 0.08
  25. Shin Maeda · 2 shared papers, 2011–2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.